TransMedics Group, Inc. (TMDX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$86.40-2.12%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
TransMedics grows revenue about 23% yearly, reaching ~$742M in 2026. Gross profit improved from $88M to $101M in one year. Cash flow from operations turned positive, rising to $24.5M in 2026-Q1. The company leads in organ transplant technology with growth potential.
Recent earnings missed expectations by 50%, and guidance was cut. Profit margins and cash flow improvements face challenges. Market concerns about heart market weakness pressure growth prospects.
The stock trades about 19% below our fair value near $88, reflecting analyst expectations of 23% revenue growth. Our fair value is 26% below the Street median, indicating cautious optimism versus more bullish views.
Breaks if: Gross profit falls below $88M in 2026-Q1
Focus on expanding gross margins through operational efficiencies and product mix improvements despite investments and cost pressures.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a durable compounder, with a focus on revenue growth. The current thesis state is intact, supported by strong financial results, but the elevated risk factors and expensive valuation create caution.
The market has priced in a high valuation, reflecting a premium compared to peers. There is an expectations gap, indicating that investors may anticipate continued strong performance despite recent earnings misses.
Management is focused on expanding revenue growth, which has been successful recently. However, improvements in gross profit margins and cash flow from operations have shown mixed results, indicating potential challenges ahead.
The thesis hinges on the ability of TMDX to maintain revenue growth while managing costs effectively. Additionally, the performance of sector bellwethers and overall economic conditions will significantly influence the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has raised concerns about management's execution. This miss follows a recent commitment from management, which now appears to be lagging.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Gross margin was 60% in 2026-Q2, slightly down from 61% in 2025-Q2, and 58% in 2026-Q1 versus 61% in 2025-Q1, reflecting investments and cost pressures. Management highlights sequential gross margin expansion but financials show a slight decline year-over-year, indicating limited progress on margin improvement.
“CEO: 'Record revenue, accelerating service growth, and sequential gross margin expansion, all as we invested aggressively in our strategic priorities.'”
“Gross margin for 2026-Q1 was 58%, compared to 61% in 2025-Q1, impacted by investments to support growth and scale.”
“Gross margin was 61% in 2025-Q4, consistent with prior periods.”
Breaks if: Operating cash flow falls below $0 in 2026-Q1
Improve operating cash flow through revenue growth and operational efficiencies to support investments and growth initiatives.
Stated as a priority in 3 of last 3 quarters. Cash from operations declined from $69.6M in 2025-Q3 to $24.5M in 2026-Q1, showing volatility and a downward trend. Despite management focus, operating cash flow has not consistently improved, indicating limited progress on enhancing cash flow.
“Cash from operating activities was $24.5 million in 2026-Q1.”
“Cash from operating activities was $34.5 million in 2025-Q4.”
“Cash from operating activities was $69.6 million in 2025-Q3.”
Breaks if: Revenue falls below $727M in FY26
Focus on growing total revenue through increased utilization of Organ Care System and expansion of National OCS Program and logistics services.
Stated as a priority in 3 of last 3 quarters. Total revenue grew 21% from $157.4M in 2025-Q2 to $189.9M in 2026-Q2. Full year 2026 revenue guidance was raised to $737M-$757M, representing 22%-25% growth over prior year. Management is delivering on revenue growth with consistent quarterly increases and raised guidance.
“CEO: 'We are building TransMedics to remain a growth company... deploying capital behind four distinct growth opportunities... expand access and improve outcomes.'”
“CEO: 'We are laser focused on executing our multi-pronged growth strategy by accelerating ENHANCE heart and DENOVO lung programs... launching our NOP model in Europe, and advancing our OCS Kidney pro…”
“Company: 'Expect total revenue for full year 2026 to be in range of $727 million to $757 million, representing 20% to 25% growth compared to prior year.'”
In the 1-3 year view, TMDX's strong revenue growth is promising, but elevated risks and an expensive valuation warrant careful monitoring. Not investment advice.